BRONJ(bisphosphonate related osteonecrosis of jaw)의 진단과 치료

Diagnosis and Management of BRONJ(bisphosphonate related osteonecrosis of jaw)

  • 팽준영 (삼성서울병원 구각악안면외과)
  • Paeng, Jun-Young (Department of Oral and Maxillofacial Surgery, Samsung Medical Center)
  • 발행 : 2011.07.01

초록

BRONJ(Bisphosphonate Related Osteonecrosis of Jaws) is not easy to be managed because it responds less predictably to established surgical treatment algorithms for osteomyelitis or osteoradionecrosis. The guidelines recommend that any kind of surgery should be delayed if possible. In the latest stage-dependent recommendations of the AAOMS in 2009, a conservative regime with antibiotics, antibacterial mouthe rinses and pain control in stages 0 to II. Some investigators have described the benefits of early osteotomy with primary wound closure. However, there are only a few publications with a standardized surgical concepts. In this reviews, various aspects of diagnosis and management of BRONJ will be discussed.

키워드

참고문헌

  1. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-- 2009 update. J Oral Maxillofac Surg. 2009 May 1 ;67(5 Suppl) :2-12.
  2. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996 Feb.; 18(2) :75-85. https://doi.org/10.1016/8756-3282(95)00445-9
  3. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer journal (Sudbury, Mass.). 2001 Aug.;7(5):377-387.
  4. Arce K, Assael LA, Weissman JL, Markiewicz MR. Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg. 2009 May 1;67(5 Suppl):75-84.
  5. BIANCHI S, Scoletta M, CASSIONE F, MIGLIARETTI G, Mozzati M. Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Aug.; 104(2) :249-258. https://doi.org/10.1016/j.tripleo.2007.01.040
  6. Bedogni A, Blandamura S, Lokmic Z, Palumbo C, Ragazzo M, Ferrari F, et al. Bisphosphonateassociated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Mar. 1; 105(3) :358-364. https://doi.org/10.1016/j.tripleo.2007.08.040
  7. Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologlc analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med. 2006 Mar.; 35(3) : 155-160. https://doi.org/10.1111/j.1600-0714.2006.00391.x
  8. Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007 Dec. 1 ;65(12):2397-2410. https://doi.org/10.1016/j.joms.2007.08.003
  9. American Society for Bone and Mineral Research Task Force on Osteonecrosis of the Jaw, Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, et al. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2008 Jun.; 66(6) : 1320-1; author reply 1321-2.
  10. Fantasia JE. Bisphosphonates--what the dentist needs to know: practical considerations. J Oral Maxlllofac Surg. 2009 May 1 ;67(5 Suppl) :53-60.
  11. Vescovi P, Manfredi M, Merigo E, Meleti M. Early surgical approach preferable to medical therapy for bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2008 Apr.;66(4):831-832. https://doi.org/10.1016/j.joms.2007.11.025
  12. Marx RE, Sawatari y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteone crosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxllfofac Surg. 2005 Nov. ;63(11): 1567-1575. https://doi.org/10.1016/j.joms.2005.07.010
  13. Sedghizadeh PP, Kumar SKS, Gorur A, Schaudinn C, Shuler CF, Costerton JW. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg. 2008 Apr.;66(4):767-775. https://doi.org/10.1016/j.joms.2007.11.035
  14. Hoefert S, Eufinger H. Relevance of a prolonged preoperative antibiotic regime in the treatment of bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg. 2011 Feb. 1 ;69(2) :362-380. https://doi.org/10.1016/j.joms.2010.06.200
  15. Thumbigere-Math V, Sabino MC, Gopalakrishnan R, Huckabay S, Dudek AZ, Basu S, et al. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg. 2009 Sep. 1; 67(9) : 1904-1913. https://doi.org/10.1016/j.joms.2009.04.051
  16. Badros A. Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk Factors. Journal of Clinical Oncology. 2006 Jan. 17; 24(6) : 945-952. https://doi.org/10.1200/JCO.2005.04.2465
  17. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteo necrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008 Sep.;44(9) :857-869. https://doi.org/10.1016/j.oraloncology.2007.11.012
  18. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. YJOMS. 2003 Sep.;61(9):1115-1117.
  19. Lam DK, S?ndor GKB, Holmes HI, Evans AW, Clokie CML A review of bisphosphonate-associated osteonecrosis of the Jaws and its management. Journal (Canadian Dental Association). 2007 Jun.;73(5):417-422.
  20. Stockmann P, Vairaktaris E, Wehrhan F, Selss M, Schwarz S, Spriewald B, et al. Osteotomy and primary wound closure in blsphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer. 2010 Apr.;18(4) : 449--460. https://doi.org/10.1007/s00520-009-0688-1
  21. Pautke C, Bauer F, Otto S, Tischer T, Steiner T, Weitz J, et al Fluorescence-guided. bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective. pilot study. J Oral Maxillofac Surg. 2011;69(1):84-91. https://doi.org/10.1016/j.joms.2010.07.014
  22. Mucke T, Koschinski J, Deppe H, Wagenpfeil S, Pautke C, Mitchell DA, et al. Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws. J Cancer Res Clin Oncol. 2010 Oct 7;
  23. Carlson ER, Basile JD. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009 May 1;67(5 Suppl):85-95.
  24. Bone HG, Hosking D, Devogelaer J-P, Tucci JR, Emkey RD, Tonino RP, et al. Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women. N Engl J Med. 2004 Mar. 18;350(12): 1189-1199. https://doi.org/10.1056/NEJMoa030897
  25. Adornato MC, Morcos I, Rozanski J. The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. J Am Dent Assoc. 2007 Jul.; 138(7) :971-977. https://doi.org/10.14219/jada.archive.2007.0294
  26. Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. YJOMS. 2007 Mar.;65(3);573-580.
  27. Agrillo A, Ungari C, Filiaci F. Priore P, lannetti G. Ozone therapy in the treatment of avascular bisphosphonate-related jaw osteonecrosis. J Craniofac Surg. 2007 Sep.; 18(5) : 1071-1075. https://doi.org/10.1097/scs.0b013e31857261f
  28. Freiberger JJ. Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the Jaws. J Oral Maxillofac Surg. 2009 May 1 ;67(5 Suppl):96-106.